Adoption of antithrombotic stewardship and utilization of clinical decision support systems-A questionnaire-based survey in Dutch hospitals.

Autor: Jetske Graafsma, Joanna E Klopotowska, Hieronymus J Derijks, Ewoudt M W van de Garde, Rien H L Hoge, Marieke J H A Kruip, Karina Meijer, Fatma Karapinar-Carkit, Patricia M L A van den Bemt

Publikováno v: PLoS ONE, Vol 19, Iss 6, p e0306033 (2024)

Antithrombotics require careful monitoring to prevent adverse events. Safe use can be promoted through so-called antithrombotic stewardship. Clinical decision support systems (CDSSs) can be used to monitor safe use of antithrombotics, supporting anti

Externí odkaz: https://doaj.org/article/fb72e9f2b4574e468baef9ed9a092c6d

Renal function-based versus standard dosing of pemetrexed: a randomized controlled trial

Autor: Nikki de Rouw, René J. Boosman, Jacobus A. Burgers, Alwin D. R. Huitema, Anne-Marie C. Dingemans, Hieronymus. J. Derijks, David M. Burger, Berber Piet, Lizza E. L. Hendriks, Bonne Biesma, Melinda A. Pruis, Daphne W. Dumoulin, Sander Croes, Ron H. J. Mathijssen, Michel M. van den Heuvel, Rob ter Heine

Publikováno v: Cancer Chemotherapy and Pharmacology, 91, 33-42
Cancer Chemotherapy and Pharmacology, 91(1), 33-42. Springer Verlag
Cancer Chemotherapy and Pharmacology, 91(1), 33-42. Springer-Verlag
Cancer Chemotherapy and Pharmacology, 91, 1, pp. 33-42

Item does not contain fulltext PURPOSE: Pemetrexed is a chemotherapeutic drug in the treatment of non-small cell lung cancer and mesothelioma. Optimized dosing of pemetrexed based on renal function instead of body surface area (BSA) is hypothesized t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f89d8fdab2aea47b4e702192ee6d7831
https://hdl.handle.net/2066/290955

A Systematic Evaluation of Cost-Saving Dosing Regimens for Therapeutic Antibodies and Antibody-Drug Conjugates for the Treatment of Lung Cancer

Autor: Rob ter Heine, Michel M. van den Heuvel, Berber Piet, Maarten J. Deenen, Anthonie J. van der Wekken, Lizza E. L. Hendriks, Sander Croes, Robin M. J. M. van Geel, Frank G. A. Jansman, Rogier C. Boshuizen, Eric J. F. Franssen, Arthur A. J. Smit, Daphne W. Dumoulin, Thijs H. Oude Munnink, Egbert F. Smit, Hieronymus J. Derijks, Cor H. van der Leest, Jeroen J. M. A. Hendrikx, Dirk J. A. R. Moes, Nikki de Rouw

Publikováno v: Targeted Oncology, 18, 3, pp. 441-450
Targeted Oncology, 18(3), 441-450. Springer Paris
Targeted Oncology, 18, 441-450

Contains fulltext : 292912.pdf (Publisher’s version ) (Open Access) BACKGROUND: Expensive novel anticancer drugs put a serious strain on healthcare budgets, and the associated drug expenses limit access to life-saving treatments worldwide. OBJECTIV

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20b4dad43b54aa2ad8708876b6bbe71a
https://repository.ubn.ru.nl/handle/2066/292912

A limited sampling schedule to estimate individual pharmacokinetics of pemetrexed in patients with varying renal functions

Autor: Michel M van den Heuvel, David M. Burger, Rob ter Heine, Sabine Visser, Stijn L.W. Koolen, Joachim G.J.V. Aerts, Hieronymus J. Derijks, Nikki de Rouw

Publikováno v: Cancer Chemotherapy and Pharmacology, 85, 231-235
Cancer Chemotherapy and Pharmacology
Cancer Chemotherapy and Pharmacology, 85, 1, pp. 231-235
Cancer Chemotherapy and Pharmacology, 85, 231-235. Springer-Verlag

Purpose Pemetrexed is a widely used cytostatic agent with an established exposure–response relationship. Although dosing is based on body surface area (BSA), large interindividual variability in pemetrexed plasma concentrations is observed. Therape

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e9c8e30d0284fa1a409d2b5bacf9f0a
https://hdl.handle.net/2066/218115

Hyperhydration with cisplatin does not influence pemetrexed exposure

Autor: Rene J. Boosman, Ron H.J. Mathijssen, Joachim G.J.V. Aerts, Hieronymus J. Derijks, Sander Croes, David M. Burger, Luuk B. Hilbrands, Stijn L.W. Koolen, Alwin D. R. Huitema, Michel M van den Heuvel, Jacobus A. Burgers, Lizza E.L. Hendriks, Rob ter Heine, Nikki de Rouw, Anne-Marie C. Dingemans, Bonne Biesma, Berber Piet

Publikováno v: British Journal of Clinical Pharmacology, 88, 2, pp. 871-876
British Journal of Clinical Pharmacology, 88(2), 871-876. Wiley-Blackwell Publishing Ltd
British Journal of Clinical Pharmacology, 88(2), 871-876. Wiley
British Journal of Clinical Pharmacology, 88, 871-876

Contains fulltext : 249097.pdf (Publisher’s version ) (Open Access) Pemetrexed is a cytotoxic drug for first-line treatment of lung cancer. It is often combined with other anticancer drugs such as cisplatin or carboplatin. In clinical practice, hyp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f536f1912b1695b5b2b04b0a78a0710